p. 5137−5141
2476-762X
Vol.16/No.13
p. 5143−5147
2476-762X
Vol.16/No.13
p. 5149−5152
2476-762X
Vol.16/No.13
p. 5153−5158
2476-762X
Vol.16/No.13
0.05),neutrophil to lymphocyte ratio (NLR), erythrocyte distribution width (RDW), mean platelet volume (MPV) andsedimentation levels of the patient.]]>
p. 5159−5162
2476-762X
Vol.16/No.13
p. 5163−5167
2476-762X
Vol.16/No.13
p. 5169−5173
2476-762X
Vol.16/No.13
1 month) complications were lower limb lymphedema, incontinence anderysipelas. The risk factors for developing each of the complications were analyzed with regression analysis.Results: In the entire cohort, 29 (29.3%) women experienced early and 12 (12.1%) had late complications.Wound complications including infection and breakdown were the leading early complications (23.2%). In themultivariate analysis, both obesity (body mass index ≥30 kg/m2) and advanced age (≥65 years) were found asindependent predictive factors for early complications. Obese women of advanced age had 6.32 times more riskof experiencing any of the early complications, when compared to non-obese and young women (55.6% vs 8.7%).The most common late complication was lower limb lymphedema (10.1%) that was more frequently seen in youngwomen. However, neither age nor lymph node count were significantly associated with the occurrence of lowerlimb lymphedema. Conclusions: More than 40% of the women suffered from postoperative complications afteringuinofemoral lymphadenectomy in the current study. While advanced age and obesity were the significantpredictors for any of the early complications, there was no identified risk factor for lower limb lymphedema.]]>
p. 5175−5179
2476-762X
Vol.16/No.13
p. 5181−5185
2476-762X
Vol.16/No.13
p. 5187−5190
2476-762X
Vol.16/No.13
p. 5191−5197
2476-762X
Vol.16/No.13
p. 5199−5203
2476-762X
Vol.16/No.13
p. 5205−5210
2476-762X
Vol.16/No.13
p. 5211−5217
2476-762X
Vol.16/No.13
p. 5219−5223
2476-762X
Vol.16/No.13
p. 5225−5231
2476-762X
Vol.16/No.13
p. 5233−5235
2476-762X
Vol.16/No.13
p. 5237−5242
2476-762X
Vol.16/No.13
median score of 19), which was associated with education [graduates(OR=2.31; 95%CI=1.78, 3.16), post-graduates (OR=7.06; 95%CI=4.14, 12.05) compared to ≤ high school] andsocio-economic status (SES) [low-middle (OR=4.20; 95%CI=2.72, 6.49), middle (OR=6.00; 95%CI=3.82, 9.42)and upper (OR=6.97; 95%CI=4.10, 11.84) compared to low SES]. Conclusions: BC awareness of women in Delhiwas suboptimal and was associated with low SES and education. Awareness must be drastically increased viacommunity outreach and use of media as a first step in the fight against BC.]]>
p. 5243−5251
2476-762X
Vol.16/No.13
p. 5253−5256
2476-762X
Vol.16/No.13
p. 5257−5260
2476-762X
Vol.16/No.13
10 ng/ml, respectively. Theaverage Gleason score was 7.2±0.2. Some 6 (13.6%) out of 44 PCa patients had bone metastases. The sensitivitywas 80% and specificity was 81.3% at the cut-off %fPSA of 15% in PCa patients with a tPSA level below 4 ng/mL. A lower %fPSA was associated with PCa patients with Gleason score ≥7 than those with Gleason score≤6 (11.7±0.98 vs. 16.5±2.25%, P=0.029). No obvious relation of %fPSA to the incidence of bone metastasis wasapparent in this study. Conclusions: The clinical application of %fPSA could help to discriminate PCa frombenign prostate disease in men with a tPSA concentration below 4 ng/mL.]]>
p. 5261−5264
2476-762X
Vol.16/No.13
p. 5265−5271
2476-762X
Vol.16/No.13
p. 5273−5278
2476-762X
Vol.16/No.13
p. 5279−5284
2476-762X
Vol.16/No.13
p. 5285−5288
2476-762X
Vol.16/No.13
p. 5289−5296
2476-762X
Vol.16/No.13
p. 5297−5304
2476-762X
Vol.16/No.13
p. 5305−5310
2476-762X
Vol.16/No.13
p. 5311−5317
2476-762X
Vol.16/No.13
p. 5319−5323
2476-762X
Vol.16/No.13
p. 5325−5329
2476-762X
Vol.16/No.13
p. 5331−5335
2476-762X
Vol.16/No.13
p. 5337−5341
2476-762X
Vol.16/No.13
p. 5343−5348
2476-762X
Vol.16/No.13
p. 5349−5357
2476-762X
Vol.16/No.13
p. 5359−5364
2476-762X
Vol.16/No.13
p. 5365−5370
2476-762X
Vol.16/No.13
p. 5371−5376
2476-762X
Vol.16/No.13
p. 5377−5383
2476-762X
Vol.16/No.13
p. 5385−5388
2476-762X
Vol.16/No.13
p. 5389−5396
2476-762X
Vol.16/No.13
p. 5397−5400
2476-762X
Vol.16/No.13
p. 5401−5406
2476-762X
Vol.16/No.13
p. 5407−5413
2476-762X
Vol.16/No.13
p. 5415−5420
2476-762X
Vol.16/No.13
p. 5421−5425
2476-762X
Vol.16/No.13
p. 5427−5432
2476-762X
Vol.16/No.13
p. 5433−5438
2476-762X
Vol.16/No.13
p. 5439−5444
2476-762X
Vol.16/No.13
p. 5445−5451
2476-762X
Vol.16/No.13
p. 5453−5458
2476-762X
Vol.16/No.13
p. 5459−5462
2476-762X
Vol.16/No.13
p. 5463−5469
2476-762X
Vol.16/No.13
p. 5471−5476
2476-762X
Vol.16/No.13
0.05). D-D abnormal rate increased with age and was statistically significantamong different age groups (p<0.05). Regarding staging of tumor, D-D abnormal rate in patients with phaseⅠwas 2.0%, 6.2% in phase Ⅱ, 47.6% in phase Ⅲ and 83.1% in phase Ⅳ, with statistically significant differencesbetween phase Ⅲ and Ⅱ, as well as phase Ⅲ and Ⅳ (p<0.01). Conclusions: A prethrombotic state was closelyrelated to malignancy of tumors. The risk factors for a prethrombotic state include age and tumor stage.]]>
p. 5477−5482
2476-762X
Vol.16/No.13
p. 5483−5488
2476-762X
Vol.16/No.13
p. 5489−5492
2476-762X
Vol.16/No.13
p. 5493−5498
2476-762X
Vol.16/No.13
p. 5499−5505
2476-762X
Vol.16/No.13
p. 5507−5513
2476-762X
Vol.16/No.13
p. 5515−5519
2476-762X
Vol.16/No.13
p. 5521−5524
2476-762X
Vol.16/No.13
p. 5525−5529
2476-762X
Vol.16/No.13
p. 5531−5536
2476-762X
Vol.16/No.13
0.05). Conclusions: In this research, pre-treatment elevated level of platelet countdemostrated a significantrelationship with HER2 amplification/overexpression, and both variables significantlyinfluenced the prognosis of BC. However, elevated platelet count did not exhibit any association with ER, PR,Ki67 and LN involvement.]]>
p. 5537−5540
2476-762X
Vol.16/No.13
p. 5541−5547
2476-762X
Vol.16/No.13
p. 5549−5556
2476-762X
Vol.16/No.13
p. 5557−5563
2476-762X
Vol.16/No.13
p. 5565−5571
2476-762X
Vol.16/No.13
p. 5573−5578
2476-762X
Vol.16/No.13
p. 5579−5582
2476-762X
Vol.16/No.13
p. 5583−5584
2476-762X
Vol.16/No.13
p. 5585−5585
2476-762X
Vol.16/No.13
p. 5587−5587
2476-762X
Vol.16/No.13